Terminated PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02414165

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma (Toca5)

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor: Tocagen Inc.

Conditions Anaplastic Astrocytoma Glioblastoma Multiforme

Interventions Bevacizumab Lomustine Temozolomide Toca 511 Toca FC

Updated 15 times since 2017 Last updated: Feb 6, 2020 Started: Nov 30, 2015 Primary completion: May 31, 2019 Completion: Dec 20, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor Decision

Other terminated trials from Tocagen Inc.

More terminations from Tocagen Inc.

Listed as NCT02414165, this PHASE2/PHASE3 trial focuses on Anaplastic Astrocytoma and Glioblastoma Multiforme and remains terminated or withdrawn. Sponsored by Tocagen Inc., it has been updated 15 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2_PHASE3
Mar 2020 — Jan 2021 [monthly]

Terminated PHASE2_PHASE3

▶ Show 10 earlier versions

Feb 2020 — Mar 2020 [monthly]

Terminated PHASE2_PHASE3

Status: Active Not Recruiting → Terminated
Jan 2020 — Feb 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3
Dec 2018 — Jan 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Oct 2018 — Dec 2018 [monthly]

Recruiting PHASE2_PHASE3
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE2_PHASE3
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE2_PHASE3
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE2_PHASE3

Status: Active Not Recruiting → Recruiting
Nov 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE2_PHASE3
Feb 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tocagen Inc.

Data source: Tocagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Aurora, United States , Baltimore, United States , Charleston, United States , Charlottesville, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Dallas, United States , Detroit, United States and 45 more locations